This way we are able to offer scientists the newest and best research tools available globally regardless of source. Our information-rich products, together with expert customer support and fast delivery, make us the researcher’s choice. We are a global leader in the sale of research antibodies and have a reputation for providing high quality products, along with comprehensive supporting scientific data, to researchers who strive to understand the molecular basis of biology and disease. Our dual growth strategy combines organic in-house development with a track record of successfully completing partnerships and acquisitions. In addition, we operate a robust framework of systems and controls to maintain high standards throughout the Company. One area that has become increasingly attractive to us is broadening Abcam’s offerings as a development and supply partner in the diagnostics market. Consumers Our comprehensive consumer insights, personalised support, data and continually growing range of resources are helping to accelerate scientific discovery. Our customer feedback has never been stronger and we continue to make market share gains worldwide. It has been a year of progress for Abcam as we have once again delivered on our financial goals. Our research use-only product catalogue revenues at reported values grew to £202.5m (FY 2016: £159.0m), a 27.4% increase over the previous year. By product type, we continue to grow primary antibody revenue ahead of the global market growth rate. This is a model we are replicating across many commercial agreements around the world to establish future growth for our business. Our KPI performance was within full year guidance for all measures: Strategic KPIs FY 2017 FY 2017 target Growth in constant currency revenue from RabMAb ® primary antibody range 25% 23–27% Growth in constant currency revenue from non-primary antibody products 16% 15–20% Brand Net Promoter Score (NPS) 24% 24–30% Market position #1 in primary antibodies #1 #1 Abcam has consistently delivered against these strategic priorities and achieved growth rates ahead of the underlying market rate. We are investing in building enhanced capabilities, processes and systems centred around the Oracle Cloud ERP system. We are resolutely focused on delivering a high quality solution that is scalable and will deliver future efficiency improvements. The total European Research Council (ERC) budget increased to €1.8bn, an 8% increase from 2016, with approximately €600m available for new life science projects in 2017. Regular security reviews including penetration testing by external experts • Physical and software safeguards in place • IT disaster recovery processes • Cyber security insurance policy • More instances of high profile global cyber attacks • Website security penetration tested by a third party • Cyber security audit by a third party • Regular public website failover drills • Additional improved security measures identified and implementation started 1 3 2 4 17 Annual Report and Accounts 2017 Abcam plc Strategic report Table of principal risks continued Loss of output at any Group manufacturing or logistics facility Principal risk and why it is relevant Key mitigation Activity during the year Change Alignment to strategy Loss of manufacturing or logistics output at any important facility risks disruption to sales operations • Strategic location of the six manufacturing facilities across the world • Business continuity planning and disaster recovery plans • Saleable stocks of finished products held in logistics hubs globally. Back-up hybridomas are stored in more than one location • Business interruption insurance • Circa 61% of catalogue revenues come from OEM suppliers • Strict quarantine procedures for cell lines with tested procedures for responding to mycoplasma infection • Cryogenic storage and fridges are covered by alarms • Infrastructure improvements in Branford and Hangzhou to enhance security of supply • Further progress in the initiative to better align inventory holdings to sales patterns 1 3 2 4 Business growth is constrained by not having appropriate people, resources and infrastructure in place Principal risk and why it is relevant Key mitigation Activity during the year Change Alignment to strategy Abcam has enjoyed rapid growth increasing the size of our operation and the number of people we employ. Abcam is proud to be partnering with In2Science and this year launched an image competition for the students during their research placements. The expansion in gross margin comes from both product mix and productivity improvements across our manufacturing sites. 30 June 2016 Adjusted income statement £000 Acquisition- related (costs)/income £000 Incremental costs associated with the systems and improvements £000 R&D tax credit relating to prior years £000 Reported IFRS income statement £000 Revenue 171,673 — — — 171,673 Cost of sales (51,142) — — — (51,142) Gross profit 120,531 — — — 120,531 Administration and management expenses (55,231) (2,206) (3,955) — (61,392) Research and development expenses (11,662) (2,467) — 1,308 (12,821) Operating profit 53,638 (4,673) (3,955) 1,308 46,318 Operating profit margin 1 (%) 31.2% 2.7% 2.3% (0.8%) 27.0% Finance income/(expense) 144 (1,050) — — (906) Profit before tax 53,782 (5,723) (3,955) 1,308 45,412 Taxation (8,630) 994 791 (1,138) (7,983) Profit after tax 45,152 (4,729) (3,164) 170 37,429 Earnings per share (pence) Basic 22.45 (2.35) (1.57) 0.08 18.61 Diluted 22.35 (2.34) (1.56) 0.08 18.53 27 Annual Report and Accounts 2017 Abcam plc Strategic report Reconciliation of alternative profit measures 30 June 2017 £000 30 June 2017 % 30 June 2016 £000 30 June 2016 % Operating profit 55,136 25.4 46,318 27.0 Depreciation and amortisation 15,326 11,355 EBITDA 70,462 32.5 57,673 33.6 Contingent consideration – change in fair value, net of related acquisition costs (983) 466 ERP improvements 3,873 2,645 Integration costs (21) 480 R&D tax credit relating to prior years — (1,308) Adjusted EBITDA 73,331 33.8 59,956 34.9 Reconciliation of alternative cash measures 30 June 2017 £000 30 June 2016 £000 Net cash inflow from operating activities 66,384 47,314 Less: Purchase of property, plant and equipment (10,224) (7,974) Purchase of intangible assets (8,947) (7,608) Transfer of cash into escrow for future capital expenditure (6,075) — Free cash flow (FCF) 41,138 31,732 Corporate governance 29 Chairman’s governance overview 30 Directors and Company Secretary 32 Corporate governance report 37 Audit and Risk Committee 40 Nomination Committee 41 Remuneration report 55 Directors’ report I am pleased to present the Corporate Governance Report for the year ended 30 June 2017. This year I again conducted a thorough evaluation process, which was discussed in detail by the Board. There is always room for improvement and we have identified some areas around Board process to develop in the coming year. While at Ventana, she led the company to increased market leadership worldwide and primacy in companion diagnostics. She was also the founder and Chief Executive Officer of On-Q-ity, a circulating tumour cells company. Mara’s specific focus areas are in her operational expertise including acquisition integration, global manufacturing, quality systems and strategic marketing. Prior to joining Abcam, Alan spent 14 years with Bain & Company helping companies grow organically and through acquisition. Background: A chemist by training, Sue began her career at Ford Motor Co. before moving to oil company Amerada Hess. Background: Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with Dr David Cleevely and Professor Tony Kouzarides. Appointment and tendering PwC has served as Abcam’s external auditor since September 2013, when a full tender process was carried out. There has been additional oversight of this important programme at Board level with a focus on its broader reach across the Group. Within this context, I would like to provide you with an overview of the Committee’s major decisions during 2016/17. Abcam has achieved strong financial growth, while also investing significantly in the people, systems and infrastructure required to support our continued expansion. In line with policy, neither Jeff lliffe nor Jim Warwick will receive a deferred share award for the year ended 30 June 2017. The table below shows each strategic KPI measure, its relative weighting and an indication of the targets: Strategic measure Weighting Threshold Target Exceed Maximum RabMAb ® primaries CER revenue growth 13% 17%–19% 19%–21% 21%–23% >23% Non-primaries CER revenue growth 7% 19%–21% 21%–23% 23%–25% >25% NPS 10% 20%–26% 26%–30% 30%–32% >32% Market position 3% Target to maintain #1 position in research primary antibodies as well #1 or #2 in at least two other areas Achievement was as follows: Below threshold Threshold Target Exceed Maximum % of maximum 0% 25% 50% 75% 100% RabMAb ® primaries CER revenue growth  Non-primaries CER revenue growth  NPS  Market position  Overall out-turn was 59.1% of the maximum. Each NED has committed not to transfer or sell these shares during the term of their non-executive directorship. All ABP and LTIP targets will be fully disclosed after vesting, unless full disclosure would expose the business to a clear competitive risk. They can, however, sell sufficient shares to satisfy any tax liability that may arise on the release or exercise of an award. 49 Annual Report and Accounts 2017 Abcam plc Corporate governance AUDITED INFORMATION continued f) Directors’ shareholdings and share interests continued Annual Bonus Plan deferred share awards Deferred share awards made under the ABP which remain outstanding at 30 June 2017 are outlined below: Executive Directors Nil-cost options or conditional shares held as at 30 June 2016 1 Nil-cost options or conditional shares awarded during the year ended 30 June 2017 2 Award date Market price per share at award Planned vesting date Maximum nil-cost options or conditional shares held as at 30 June 2017 Alan Hirzel 27,475 9,169 26 Oct 16 816.6 pence 26 Oct 18 26,106 Jeff Iliffe 3 31,258 — 31,258 Jim Warwick 3 39,123 1,899 41,022 Gavin Wood — — — 97,856 11,068 98,386 1 These relate to the awards made in September 2013, November 2014 and October 2015 under the ABP for financial years 2012/13, 2013/14 and 2014/15, respectively. These targets are considered to be appropriately stretching and incentivising in the context of our business strategy. Louise Patten, Mara Aspinall and Sue Harris will receive an increase in fees to £70,000 per annum (2016/17: £50,000) with effect from 1 July 2017. No person has any special rights of control over the Company’s share capital and all issued shares are fully paid. • We performed specified procedures over certain account balances and transaction classes at other Group companies, including another Chinese operation. The relevant calculations are also performed manually, necessitating a substantive approach to testing that appropriate amounts of labour and overhead cost have been capitalised. For inventory manufactured in house and hybridomas, we agreed, on a sample basis, the quality test results to underlying records. For this reason, they continue to adopt the going concern basis in preparing its consolidated financial statements. It is effective for accounting periods beginning on or after 1 January 2019, with the Group’s initial date of application being 1 July 2019. Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised. The Group operates an employee share benefit trust as part of its incentive plans for UK-based employees. The Group tests whether goodwill is impaired on at least an annual basis or more frequently when there are indications of possible impairment. A number of assets were identified and their remaining useful life shortened based on the expected replacement date. The Group recognises liabilities for anticipated tax audit issues based on estimates of whether additional taxes will be due. Profit for the year Profit for the year has been arrived at after charging/(crediting): Note Year ended 30 June 2017 £000 Year ended 30 June 2016 £000 Cost of inventories recognised as an expense 54,701 41,379 Write down of inventories recognised as an expense 805 1,536 UK R&D tax credits (705) (1,848) R&D expenditure (including amortisation, excluding UK R&D tax credits) 19,270 14,669 Staff costs 8 52,663 41,492 Operating lease rentals – land and buildings 21 3,953 3,369 Auditors’ remuneration 7 205 171 Impairment (gain)/loss recognised on trade receivables 17 (693) 29 Foreign exchange differences arising on financial instruments at fair value through profit or loss (1,232) 2,404 Other net foreign exchange differences (including cash flow hedge movements reclassified from other comprehensive income) 10,780 (780) Depreciation of property, plant and equipment 14 5,613 3,879 Amortisation of intangible assets included within administration and management expenses 13 3,803 3,749 Amortisation of acquisition-related intangible assets included within administration and management expenses 13 1,527 1,260 Amortisation of acquisition-related intangible assets included within R&D expenditure 13 4,383 2,467 Loss on disposal of intangible assets 13 — 164 78 Abcam plc Annual Report and Accounts 2017 Financial statements Notes to the financial statements continued For the year ended 30 June 2017 7. It was concluded that these attributes were available for utilisation and would be utilised within the required time limits. Trade receivables are provided for based on estimated irrecoverable amounts determined by reference to past default experience. Derivative financial instruments 30 June 2017 Current Non-current Total £000 Asset £000 Liability £000 Asset £000 Liability £000 Derivatives carried at fair value through profit and loss (FVTPL) Forward exchange contracts that are not designated in hedge accounting relationships 227 (845) — — (618) Derivatives that are designated and effective as hedging instruments carried at fair value Forward exchange contracts 1,100 (1,245) 193 (99) (51) 1,327 (2,090) 193 (99) (669) 30 June 2016 Current Non-current Total £000 Asset £000 Liability £000 Asset £000 Liability £000 Derivatives carried at fair value through profit and loss (FVTPL) Forward exchange contracts that are not designated in hedge accounting relationships 6 (1,856) — — (1,850) Derivatives that are designated and effective as hedging instruments carried at fair value Forward exchange contracts 5 (7,411) — (1,231) (8,637) 11 (9,267) — (1,231) (10,487) Further details of derivative financial instruments are provided in note 24. The Group uses forward currency contracts to achieve this objective and applies hedge accounting where applicable. The Group’s customer base is predominantly representatives from government-funded institutions, pharmaceutical companies conducting research, and local distributors. Where these are not yet required for business opportunities, the excess cash is remitted and managed centrally. This exposure is managed by limiting the concentration of funds and contracts held with any individual financial institution. The fair value is remeasured on a monthly basis with reference to available forward market rates and comparative instrument pricing. The Group has satisfied all obligations under this arrangement (refer to note 24 for a reconciliation of contingent consideration). 30 June 2017 £000 30 June 2016 £000 Short-term employee benefits and fees 3,627 4,204 Post-employment benefits 165 84 Share-based payments charge 1,458 458 5,250 4,746 Directors’ transactions The Group has a licence and supply agreement for access to knock-out cell lines with Horizon Discovery Group plc, of which Jonathan Milner is a non-executive director. 98 Abcam plc Annual Report and Accounts 2017 Financial statements Company statement of changes in equity For the year ended 30 June 2017 1. Deferred tax assets and liabilities are offset where the Group has a legally enforceable right to do so. Any other changes in the book values of each loan are attributable to foreign exchange movements, and intergroup settlements. For example, biological pathways can trigger the assembly of new molecules, turn genes on and off, or spur a cell to move. Monoclonal antibodies recognise only one kind of antigen, i.e. they bind to the same site on a protein. It serves as an alternative to traditional customer satisfaction research and can be correlated with revenue growth. Investor relations 330 Cambridge Science Park Milton Road Cambridge CB4 0FL UK Email: corporate@abcam.com Phone: +44 (0)1223 696000 Website: www.abcamplc.com Financial calendar Financial year end 30 June 2017 Full year results announced 11 September 2017 Annual General Meeting 14 November 2017 Ex-dividend date for final dividend 16 November 2017 Record date for final dividend 17 November 2017 Final dividend payment 8 December 2017 108 Abcam plc Annual Report and Accounts 2017 Corporate directory The Abcam Group’s commitment to environmental issues is reflected in the production of this Annual Report which has been printed on Cocoon 100, an FSC ® certified and PCF (Process Chlorine Free) paper made from 100% post-consumer waste paper fibres.